# Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

> **NCT02805868** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Northwestern University**

## Conditions studied

- Myelofibrosis
- Polycythemia Vera
- Primary Myelofibrosis
- Thrombocytopenia

## Interventions

- **PROCEDURE:** Bone Marrow Aspiration and Biopsy
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Siltuximab

## Key facts

- **NCT ID:** NCT02805868
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-06
- **Primary completion:** 2019-02
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding
- **Last updated:** 2016-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02805868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02805868, "Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02805868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*